Stroke – $6.75 billion: An estimated 7 million Americans live with stroke-related upper limb impairments, with an additional 1 million new cases each year.
Spinal Cord Injury – $42.5 billion: There are approximately 300,000 Americans living with spinal cord injuries, with 17,000 new cases each year.
Cerebral Palsy – $7.5 billion: About 500,000 Americans have cerebral palsy, with 6,000 new diagnoses each year.
Multiple Sclerosis – $34 billion: An estimated 1 million Americans live with multiple sclerosis, with 12,000 new cases each year.
Limb Amputation – $102 billion: There are roughly 2 million Americans living with limb amputations, with 185,000 new cases each year.
Epilepsy – $81 billion: Approximately 3.4 million Americans have epilepsy, with 150,000 new cases each year.
Depression – $44 billion: Depression affects around 17 million Americans, with 3 million new diagnoses each year.
The report also mentions potential competitors in the BCI market, including Synchron, Neuralink, Paradromics, Precision, Motif, CorTec, and InBrain Neuroelectronics. These companies are at the forefront of developing innovative technologies that could revolutionize the field of neurotechnology.
Overall, Morgan Stanley’s report paints a promising picture of the BCI market, projecting significant revenue potential in the coming decades. With a total market size of $400 billion in the US alone, investors and industry leaders are taking notice of this emerging frontier in medical technology. As developments in BCI continue to progress, it will be interesting to see how this market evolves and the impact it has on healthcare and patient outcomes. market for Brain-Computer Interfaces (BCIs) is rapidly growing, with potential applications in various neurological conditions. A recent report highlighted the potential market opportunities for BCIs in different conditions, including stroke, Locked-In Syndrome, spinal cord injury, multiple sclerosis, cerebral palsy, limb amputation, epilepsy, and depression.
According to the report, there are about 12,500 individuals with critical upper limb impairment who could benefit from BCIs, representing an early market opportunity. Additionally, there are around 25,000 individuals with moderate upper and/or critical lower limb impairment who could also benefit from BCIs, representing a follow-on market opportunity.
Stroke and Locked-In Syndrome are estimated to have a market potential of $48.6 billion. While there are less than 1,000 known cases of Locked-In Syndrome in the US, there are approximately 900,000 strokes per year, with about a third of survivors experiencing disability. About 5% of stroke cases result in serious brain damage, limiting speech or movement.
Spinal Cord Injury represents a market potential of $10.8 billion, with around 300,000 people in the US living with traumatic spinal cord injuries. Approximately 20,000 new cases occur each year, with about 45,000 of these patients having severe upper limb impairment, making them potential early BCI adopters.
Multiple Sclerosis has a market potential of $9.45 billion, with approximately 1 million people in the US living with the condition. About 7,000 new diagnoses are made each year, with an estimated 7,500 individuals opting for a BCI.
Cerebral Palsy represents a market potential of $5.1 billion, with around 500,000 adults in the US living with the condition. Approximately 5,000 have severe upper limb impairment, while 80,000 have moderate upper or severe lower limb impairment.
Limb Amputation has a market potential of $4.5 billion, with about 2.5 million people in the US living with limb loss. Approximately 40% are missing an upper limb, making them potential initial BCI adopters. Phantom Limb pain could also represent a follow-on market opportunity.
Epilepsy has a market potential of $75 billion, with about 3 million adults in the US suffering from the condition. Approximately 150,000 individuals could be eligible for a BCI to treat severe seizures in the short-term.
Depression represents a market potential of $242.5 billion, with about 21 million people in the US living with depression. Approximately 2.5 million have severe, treatment-resistant depression, making them potential BCI candidates.
While the report provides valuable insights into the market potential for BCIs in various conditions, it is important for executives to focus on understanding lead indications, conducting their own research, and following pioneers in the field. By delving deeper into the unmet needs of populations living with neurological conditions, executives can better tailor their go-to-market strategies and drive innovation in the BCI industry.
